Inhibrx Competitors

INBX -  USA Stock  

USD 24.99  0.53  2.08%

Inhibrx competes with Biocardia, and Brickell Biotech; as well as few others. The company conducts business under Healthcare sector and is part of Biotechnology industry. Analyzing Inhibrx competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Inhibrx to its intrinsic valuation because they are able to contrast its competitors on a relative basis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Inhibrx competition on your existing holdings. Please see Inhibrx Correlation with its peers.

Inhibrx Competition 

 
Refresh
Return on Average Assets is likely to drop to -1.11 in 2022. Return on Average Equity is likely to drop to 7.73 in 2022. Inhibrx Total Assets are fairly stable at the moment as compared to the past year. Inhibrx reported Total Assets of 165.3 Million in 2021. Current Assets is likely to rise to about 164 M in 2022, whereas Assets Non Current are likely to drop slightly above 12.2 M in 2022.
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Inhibrx's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Inhibrx in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
20.2024.6229.04
Details
Intrinsic
Valuation
LowReal ValueHigh
22.9732.0936.51
Details
Naive
Forecast
LowNext ValueHigh
21.8826.3030.72
Details
3 Analysts
Consensus
LowTarget PriceHigh
50.0052.6755.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Inhibrx. Your research has to be compared to or analyzed against Inhibrx's peers to derive any actionable benefits. When done correctly, Inhibrx's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Inhibrx.

Inhibrx Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Inhibrx and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Inhibrx and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Inhibrx does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Inhibrx Competition Risk-Adjusted Indicators

Nowadays, there is a big difference between Inhibrx stock performing well and Inhibrx company doing well compared to the competition. There are way too many exceptions to the normal that investors can tell for sure what's good or bad unless they analyze Inhibrx's multiple risk-adjusted performance indicators. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Cross Equities Net Income Analysis

Compare Inhibrx and related stocks such as Biocardia, Bridgebio Pharma, Brainstorm Cell, and Brickell Biotech Net Income Over Time
Select Fundamental

2010201120122013201420152016201720182019202020212022
BCDA
9.7 M9.7 M305 K19 K234 K(6.7 M)(10.3 M)(12.3 M)(14 M)(14.7 M)(15 M)(13.5 M)(13.9 M)
BBIO
(30.6 M)(30.6 M)(30.6 M)(30.6 M)(30.6 M)(30.6 M)(30.6 M)(30.6 M)(130.7 M)(260.6 M)(448.7 M)(403.9 M)(414.5 M)
BCLI
(3.9 M)(3.9 M)(3.4 M)(4.9 M)(9.2 M)(8.5 M)(5 M)(5 M)(13.9 M)(23.3 M)(31.8 M)(28.6 M)(29.4 M)
BBI
(7.3 M)(7.3 M)(22.9 M)(31.2 M)(16.5 M)(9.2 M)(9 M)(13 M)(9.2 M)(23.9 M)(20.9 M)(18.8 M)(20.3 M)

Inhibrx and related stocks such as Biocardia, Bridgebio Pharma, Brainstorm Cell, and Brickell Biotech Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Inhibrx financial statement analysis. It represents the amount of money remaining after all of Inhibrx operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income to Non Controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends.

Inhibrx Competitive Analysis

The better you understand Inhibrx competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Inhibrx's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Inhibrx's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
INBX
BCDA
BBI
 2.08 
 24.99 
Inhibrx
 1.26 
 1.57 
Biocardia
 8.70 
 0.21 
Brickell
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Stock Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(90 Days Macroaxis Advice)
Number of Shares Shorted
Shares Owned by Insiders
Current Ratio
EBITDA
Current Valuation
Cash Flow from Operations
Operating Margin
Retained Earnings
Current Asset
Beta
Price to Book
Shares Outstanding
Total Debt
Return On Equity
Price to Earning
Z Score
Shares Owned by Institutions
Return On Asset
Book Value Per Share
Cash and Equivalents
Current Liabilities
Price to Earnings To Growth
Total Asset
Short Ratio
Price to Sales
Market Capitalization
Cash per Share
Net Income
Earnings Per Share
Debt to Equity
Revenue
Working Capital
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Inhibrx Competition Performance Charts

Complement your Inhibrx position

In addition to having Inhibrx in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Healthcare Thematic Idea Now

Healthcare
Healthcare Theme
Fama and French focuses on testing asset pricing under different economic assumptions. Healthcare theme has 61 constituents.
View All  Next Launch Healthcare
Please see Inhibrx Correlation with its peers. Note that the Inhibrx information on this page should be used as a complementary analysis to other Inhibrx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bond Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for Inhibrx Stock analysis

When running Inhibrx price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Is Inhibrx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibrx. If investors know Inhibrx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibrx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Inhibrx is measured differently than its book value, which is the value of Inhibrx that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibrx's value that differs from its market value or its book value, called intrinsic value, which is Inhibrx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibrx's market value can be influenced by many factors that don't directly affect Inhibrx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibrx's value and its price as these two are different measures arrived at by different means. Investors typically determine Inhibrx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibrx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.